Holen Sie sich die Stockscreener-App
252.97
0.38%
0.695
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RMD?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$252.27
Offen:
$255
24-Stunden-Volumen:
147.36K
Relative Volume:
0.15
Marktkapitalisierung:
$36.96B
Einnahmen:
$5.26B
Nettoeinkommen (Verlust:
$1.44B
KGV:
25.89
EPS:
9.7713
Netto-Cashflow:
$1.76B
1W Leistung:
+1.28%
1M Leistung:
+3.59%
6M Leistung:
+1.56%
1J Leistung:
+6.17%
1-Tages-Spanne:
$252.66
$255.83
1-Wochen-Bereich:
$245.97
$259.99
52-Wochen-Spanne:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Firmenname
Resmed Inc
Sektor
Telefon
(858) 746-2400
Adresse
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Vergleichen Sie RMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
253.20 | 36.82B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
ISRG
Intuitive Surgical Inc
|
553.94 | 192.25B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
199.19 | 57.34B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
79.28 | 38.71B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
WST
West Pharmaceutical Services Inc
|
267.05 | 19.25B | 2.96B | 487.70M | 344.00M | 6.6758 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-18 | Eingeleitet | Citigroup | Buy |
| 2025-09-02 | Hochstufung | CLSA | Hold → Outperform |
| 2025-07-15 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-01-16 | Eingeleitet | Goldman | Buy |
| 2025-01-10 | Eingeleitet | Piper Sandler | Neutral |
| 2024-12-13 | Eingeleitet | Stifel | Hold |
| 2024-09-24 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-09-18 | Herabstufung | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Herabstufung | Needham | Buy → Hold |
| 2024-06-25 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-06 | Fortgesetzt | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Hochstufung | Needham | Hold → Buy |
| 2023-09-05 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Eingeleitet | UBS | Buy |
| 2023-04-14 | Eingeleitet | Mizuho | Buy |
| 2023-01-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-10-20 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-10-12 | Eingeleitet | Jefferies | Hold |
| 2022-09-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-08-15 | Herabstufung | CLSA | Buy → Outperform |
| 2022-08-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-08-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-01-31 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-01-31 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-28 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Hochstufung | CLSA | Outperform → Buy |
| 2022-01-13 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-10-22 | Hochstufung | CLSA | Underperform → Outperform |
| 2021-08-02 | Herabstufung | CLSA | Outperform → Sell |
| 2021-08-02 | Herabstufung | Needham | Buy → Hold |
| 2021-07-28 | Hochstufung | Jefferies | Underperform → Hold |
| 2021-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Eingeleitet | RBC Capital Mkts | Underperform |
| 2021-06-28 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-06-22 | Hochstufung | Macquarie | Neutral → Outperform |
| 2021-06-22 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-06-21 | Bestätigt | Needham | Buy |
| 2021-06-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Hochstufung | CLSA | Sell → Outperform |
| 2021-05-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-04-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-03-16 | Hochstufung | Needham | Hold → Buy |
| 2020-11-02 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Eingeleitet | CLSA | Underperform |
| 2020-01-31 | Herabstufung | UBS | Buy → Neutral |
| 2020-01-10 | Eingeleitet | Oppenheimer | Perform |
| 2019-11-22 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Hochstufung | UBS | Neutral → Buy |
| 2019-07-16 | Herabstufung | UBS | Buy → Neutral |
| 2019-05-06 | Hochstufung | UBS | Neutral → Buy |
| 2019-04-18 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Herabstufung | Goldman | Buy → Neutral |
| 2019-01-25 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Eingeleitet | Goldman | Buy |
Alle ansehen
Resmed Inc Aktie (RMD) Neueste Nachrichten
Mick Farrell, Chairman and CEO of Resmed, Named Chair of AdvaMed Board of Directors - WebWire
Is ResMed stock underperforming the S&P 500? - MSN
ResMed Inc. $RMD Shares Acquired by Neuberger Berman Group LLC - MarketBeat
MASTERINVEST Kapitalanlage GmbH Takes $3.02 Million Position in ResMed Inc. $RMD - MarketBeat
FORA Capital LLC Purchases New Stake in ResMed Inc. $RMD - MarketBeat
ResMed Inc announces proposed sale of securities by director - MSN
What analysts say about ResMed Inc stockEarnings Call Summaries & Breakthrough Profit Margins - earlytimes.in
Loss Report: Will ResMed Inc stock benefit from automationJuly 2025 Recap & Reliable Breakout Stock Forecasts - moha.gov.vn
ResMed stock price target raised to $345 from $335 at UBS - Investing.com
Ilex Capital Partners UK LLP Takes $39.31 Million Position in ResMed Inc. $RMD - MarketBeat
Bayesian Capital Management LP Buys Shares of 17,316 ResMed Inc. $RMD - MarketBeat
AdvaMed Names Resmed CEO Mick Farrell as Next Board Chair - Medical Product Outsourcing
ResMed Inc. $RMD Shares Sold by Frontier Capital Management Co. LLC - MarketBeat
ResMed Inc. $RMD Shares Purchased by State Street Corp - MarketBeat
FDA clearances: Medtronic, Insulet, Resmed - Modern Healthcare
Cerity Partners LLC Acquires 29,205 Shares of ResMed Inc. $RMD - MarketBeat
CW Advisors LLC Cuts Stock Holdings in ResMed Inc. $RMD - MarketBeat
MIN and ResMed: 2 ASX Shares Under The Valuation Microscope - Kalkine Media
ResMed (NYSE:RMD) Shares Gap UpHere's What Happened - MarketBeat
Why Resmed Shares Are Gaining Attention - TipRanks
Jump Financial LLC Takes Position in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Stock Position Raised by Axa S.A. - MarketBeat
ResMed (NYSE:RMD) S&P 500 ETF Digital Health Leadership - Kalkine Media
ResMed Director Increases Stake with New Stock Acquisition - MSN
ResMed and Netwealth: Two ASX Names Drawing Market Attention - Kalkine Media
ResMed CEO Reports Strategic Stock Transactions - TipRanks
Resmed CEO Farrell sells $1.25 million in shares By Investing.com - Investing.com Nigeria
Resmed CEO Farrell sells $1.25 million in shares - Investing.com
Resmed Insider Sold Shares Worth $1,254,796, According to a Recent SEC Filing - marketscreener.com
California Public Employees Retirement System Raises Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Inc. $RMD Shares Sold by 2Xideas AG - MarketBeat
Shares of Resmed Fall After Securing FDA Clearance for a Device Recommending Personalized Comfort Settings - marketscreener.com
ResMed receives FDA clearance for PTCS to be marketed as Smart Comfort - TipRanks
Resmed wins FDA clearance for AI-enabled personalized CPAP therapy device - MassDevice
Resmed (RMD) Achieves FDA Clearance for Smart Comfort Device - GuruFocus
Resmed (NYSE: RMD) gets FDA clearance for AI Smart Comfort built on 100M sleep nights - Stock Titan
Is ResMed Stock Underperforming the S&P 500? - Yahoo Finance
Edgestream Partners L.P. Has $456,000 Stock Holdings in ResMed Inc. $RMD - MarketBeat
Amundi Sells 211,218 Shares of ResMed Inc. $RMD - MarketBeat
Is It Too Late To Consider ResMed After Obesity and Sleep Apnea Headlines? - Yahoo Finance
How Low Can ResMed Stock Really Go? - Trefis
Peter Farrell Sells 2,000 Shares of ResMed (NYSE:RMD) Stock - MarketBeat
Invesco Ltd. Has $563.42 Million Holdings in ResMed Inc. $RMD - MarketBeat
How ResMed Inc. (Common Stock) (RMEA) stock reacts to fiscal policies2025 Top Decliners & Free Low Drawdown Momentum Trade Ideas - Newser
Is ResMed Inc. (Common Stock) (RMEA) stock inflation resilient2025 Momentum Check & Real-Time Market Trend Scan - Newser
Baird Financial Group Inc. Has $51.44 Million Holdings in ResMed Inc. $RMD - MarketBeat
1832 Asset Management L.P. Grows Position in ResMed Inc. $RMD - MarketBeat
Will ResMed Inc. (Common Stock) (RMEA) stock deliver stable dividends2025 Performance Recap & Reliable Intraday Trade Plans - Newser
Does ResMed Inc. stock trade below intrinsic valueQuarterly Trade Review & Safe Entry Point Identification - Newser
Is ResMed Inc. stock among top earnings plays2025 Geopolitical Influence & Daily Risk Controlled Trade Plans - Newser
Is ResMed Inc. (Common Stock) (RMEA) stock nearing a technical breakoutRate Hike & Daily Growth Stock Investment Tips - Newser
Finanzdaten der Resmed Inc-Aktie (RMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
1.23%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):